Drug Discovery News and Research

RSS

The drug discovery process begins with recognizing a disease or clinical condition in which there is a lack of adequate medical treatment. Once a potential drug has been identified, pre-clinical research can begin. This process includes several stages; the first of which involves identifying and validating the prospective drug’s target through assay development, high throughput screening, hit identification and finally, lead optimization. Once the pre-clinical process is complete, the newly synthesized drug candidate is selected for future clinical development.

Structure of the SARS-CoV-2 spike protein provides clues to its evolution

Researchers at the Francis Crick Institute have characterized the structure of the SARS-CoV-2 spike protein as well as its most similar relative in a bat coronavirus. The structures provide clues about how the spike evolved and could help inform vaccine design.

9 Jul 2020

Optibrium and NCSSM celebrate 5 years of education support collaboration

Optibrium, a leading provider of software and services for drug discovery, and the North Carolina School of Science and Mathematics, the states leading high school for science, technology and math education, are celebrating five years of an education support collaboration.

9 Jul 2020

PRMT5 inhibitors can help treat advanced melanoma

Scientists at Sanford Burnham Prebys Medical Discovery Institute have demonstrated the therapeutic potential of PRMT5 inhibitors to sensitize unresponsive melanoma to immune checkpoint therapy.

9 Jul 2020

Horizon Discovery introduces Cas9 and dCas9-VPR stable cell lines to simplify and accelerate CRISPR gene editing workflows

Horizon Discovery Group plc, today announced the introduction of its stably expressing Cas9 and dCas9-VPR cell lines to help accelerate gene knockout.

8 Jul 2020

Characterizing Polymorphs and Amorphous Form

Dr. Matteo Daldosso and Dr. Sebastian Wegner discuss novel solutions for the characterization of polymorphs and amorphous form APIs.

From Bruker BioSpin Group 8 Jul 2020

Innovative clinical trial platform launched to accelerate testing of COVID-19 drugs

The University of Liverpool, Liverpool School of Tropical Medicine and Southampton Clinical Trials Unit announced this week that they have launched their innovative COVID-19 drug testing platform, AGILE.

8 Jul 2020

Researchers develop bioprinted skin model of cutaneous squamous cell carcinoma

The cover for issue 27 of Oncotarget features "Bimodal imaging examples of control and treated tumors (red) before and after the treatment period," by Browning, et al. and reported that the authors developed a 3-dimensional bioprinted skin model of cutaneous squamous cell carcinoma (cSCC) tumors together with a microscopy assay to test chemotherapeutic effects in tissue.

7 Jul 2020

Scientists identify compounds that block replication of COVID-19 virus

As the death toll from the COVID-19 pandemic mounts, scientists worldwide continue their push to develop effective treatments and a vaccine for the highly contagious respiratory virus.

7 Jul 2020

BU researchers develop new method to better understand cell communication

Researchers from Boston University School of Medicine have developed and implemented a new way to better understand how human cells communicate with each other, how this communication is disrupted in human diseases and how this can be corrected pharmacologically.

6 Jul 2020

Study suggests new potential strategy to fight against pancreatic cancer

A University of Michigan-led study is shedding new light on the way pancreatic cancer cells turn nearby connective tissue cells into co-conspirators in their deadly growth.

6 Jul 2020

New vitamin K-based drug eliminates medication-resistant epileptic seizures in mice

In the cover article of the June 11 issue of the Journal of Medicinal Chemistry, a team of researchers at the Medical University of South Carolina, led by Sherine Chan, Ph.D., and James Chou, Ph.D., reports that a new vitamin K-based drug has proved effective in mouse models of medication-resistant seizures.

6 Jul 2020

New drug discovery shows promise in fighting acute respiratory illnesses

A collaboration between the University of Toronto's Faculty of Dentistry and the National Jewish Health in Denver -- the top-ranked respiratory research hospital in the U.S. -- has yielded a new drug discovery that could be useful to combat inflammation of all varieties and shows promise in fighting acute respiratory illnesses such as COVID-19.

2 Jul 2020

Common asthma drug may offer potential as treatment for Alzheimer's disease

A new study reveals that the common asthma drug salbutamol may offer potential as a treatment for Alzheimer's disease.

1 Jul 2020

Irresistin: a ‘poison arrow’ to defeat antibiotic resistance

News-Medical speaks to Dr. James Martin and Dr. Zemer Gitai from Princeton University about their research which led to the discovery of a new antibiotic.

1 Jul 2020

Bioengineered uterine tissue can support normal pregnancies, study shows

In new research from the Wake Forest Institute for Regenerative Medicine (WFIRM), scientists have shown that bioengineered uteri supported fertilization, fetal development, and live birth with normal offspring.

29 Jun 2020

Clinically approved drugs could disrupt SARS-CoV-2 from hijacking cells

An international team of researchers has analyzed how SARS-CoV-2, the virus that causes COVID-19, hijacks the proteins in its target cells.

29 Jun 2020

3D structure of Aβ protein assemblies reveals a new mechanism of toxicity

The brains of millions of people suffering from Alzheimer´s disease (AD) are slowly and inescapably being depleted of neurons, which leads to the characteristic loss of memory and cognitive function associated with this condition.

29 Jun 2020

Sanford Burnham Prebys announces research agreement with Lilly to identify COVID-19 antibodies

Sanford Burnham Prebys Medical Discovery Institute today announced a research agreement with Eli Lilly and Company (Lilly) to characterize Lilly's next-generation anti-SARS-CoV-2 antibodies.

29 Jun 2020

WFIRM and Oracle Health Sciences team up to pair Body-on-a-Chip with data analytics

The Wake Forest Institute for Regenerative Medicine and Oracle Health Sciences have teamed as part of the Innovation Quarter's iQ Healthtech Labs to develop a consortium of industry, government, and academic members that will study novel approaches to establishing the safety of new drugs that are nearing clinical investigation in humans and FDA approval.

26 Jun 2020